(Q37981739)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309435%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309435%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309435%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Pascal Demoly

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309435%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

M Calderón

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309435%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

EAACI 100 Years of Immunotherapy Experts Panel

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309435%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

6 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309435%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309435%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309435%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309435%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

462-476

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309435%20AND%20SRC:MED&resulttype=core&format=json

The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

European Academy of Allergy and Clinical Immunology task force report on 'dose-response relationship in allergen-specific immunotherapy'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

21 January 2018

Immunotherapy in Europe

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Determinants of patient compliance with allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Cluster protocols in SCIT: enough evidence for practical use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Administration regimens for sublingual immunotherapy to pollen allergens: what do we know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Sensitization patterns to food and inhalant allergens in childhood: a comparison of non-sensitized, monosensitized, and polysensitized children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Multiallergen immunotherapy for allergic rhinitis and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Treatment of peanut allergy with rush immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Oral peanut immunotherapy in children with peanut anaphylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Safety of a peanut oral immunotherapy protocol in children with peanut allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Clinical efficacy and immune regulation with peanut oral immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Oral desensitizing treatment in food allergy: clinical and immunological results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Long-term clinical efficacy of grass-pollen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Specific immunotherapy is effective in the prevention of new sensitivities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Allergic rhinitis and its impact on asthma update: allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Duration of allergen immunotherapy in respiratory allergy: when is enough, enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

European allergen extract units and potency: review of available information.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Sublingual desensitization in patients with wasp venom allergy: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Vaccination with genetically engineered allergens prevents progression of allergic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

From allergen genes to allergy vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Recombinant allergens: what does the future hold?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Specific oral tolerance induction in children with very severe cow's milk–induced reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X

Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02785.X